Table 1.
Comparison of clinical characteristics between AML patients with higher and lower lncRNA risk scores in the training cohort.
| Variables | Total (n = 183) | Lower score (n = 91) | Higher score (n = 92) | P value |
|---|---|---|---|---|
| Sexa | 0.372 | |||
| Male | 105 | 49 (53.8%) | 56 (60.9%) | |
| Female | 78 | 42 (46.2%) | 36 (39.1%) | |
| Age (year)b | 57 (18.4–91.3) | 52.7 (19.1–91.3) | 61.5 (18.4–89.8) | 0.020 |
| Lab datab | ||||
| WBC (/μL) | 29,170 (890–423,720) | 25,110(1020–423,720) | 34,155 (890–417,500) | 0.582 |
| Hb (g/dL) | 8.1 (2.5–14.0) | 8.1 (3.7–14.0) | 8.1 (2.5–13.2) | 0.621 |
| Platelet (×1000/μL) | 44 (5–396) | 38 (6–396) | 56.5 (5–361) | 0.028 |
| Blast (/μL) | 13,439 (0–398,297) | 10,938 (0–398,296) | 15,016 (0–369,070) | 0.863 |
| LDH (U/L) | 1062 (242–8116) | 1120 (279–7400) | 982 (242–8116) | 0.419 |
| FABa | ||||
| M0 | 2 (1.1%) | 0 (0%) | 2 (2.2%) | 0.497 |
| M1 | 37 (20.2%) | 24 (26.4%) | 13 (14.1%) | 0.044 |
| M2 | 59 (32.2%) | 38 (41.8%) | 21 (22.8%) | 0.007 |
| M4 | 68 (37.2%) | 25 (27.5%) | 43 (46.7%) | 0.009 |
| M5 | 14 (7.7%) | 2 (2.2%) | 12 (13.0%) | 0.010 |
| M6 | 3 (1.5%) | 2 (2.2%) | 1 (1.1%) | 0.621 |
| 2016 WHO classificationa | ||||
| AML with t(8;21)(q22;q22.1) | 16 (8.7%) | 13 (14.3%) | 3 (3.3%) | 0.009 |
| AML with inv.(16)(p13.1q22) or t(16;16)(p13.1;q22) | 6 (3.3%) | 4 (4.4%) | 2 (2.2%) | 0.444 |
| AML with t(9;11)(p21.3;q23.3) | 3 (1.6%) | 0 (0.0%) | 3 (3.3%) | 0.246 |
| AML with t(6;9)(p23;q34.1) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | >0.999 |
| AML with (q21.3q26.2) or t(3;3)(q21.3;q26.2) | 2 (1.1%) | 1 (1.1%) | 1 (1.1%) | >0.999 |
| AML with mutated NPM1 | 59 (32.2%) | 29 (31.9%) | 30 (32.6%) | >0.999 |
| AML with biallelic mutations of CEBPA | 18 (9.8%) | 17 (18.7%) | 1 (1.1%) | <0.001 |
| AML with myelodysplasia-related changes | 19 (10.4%) | 7 (7.7%) | 12 (13.0%) | 0.333 |
| AML, NOS | ||||
| AML with minimal differentiation | 1 (0%) | 0 (0%) | 1 (0.5%) | >0.999 |
| AML without maturation | 14 (7.7%) | 5 (5.5%) | 9 (9.8%) | 0.405 |
| AML with maturation | 30 (16.4%) | 11 (12.1%) | 19 (20.7%) | 0.162 |
| Acute myelomonocytic leukemia | 12 (6.6%) | 3 (3.3%) | 9 (9.8%) | 0.133 |
| Acute monoblastic/monocytic leukemia | 2 (1.1%) | 0 (0%) | 2 (2.2%) | 0.497 |
| Pure erythroid leukemia | 1 (0.5%) | 1 (1.1%) | 0 (0%) | 0.497 |
| Induction responsea, c | ||||
| CR | 82 (69.5%) | 51 (78.5%) | 31 (58.5%) | 0.027 |
| PR/Refractory | 28 (23.7%) | 11 (16.9%) | 17 (32.1%) | 0.081 |
| Induction death | 8 (6.8%) | 3 (4.6%) | 5 (9.4%) | 0.466 |
| Relapse | 54 (65.9%) | 30 (58.8%) | 24 (77.4%) | 0.098 |
Abbreviations: FAB, French-American-British classification; CR, complete remission; WHO, World Health Organization; NOS, not otherwise specified; PR, partial remission.
a
number of patients (%).
b
median (range).
c
Totally 118 patients received standard chemotherapy, 65 in the low-score group and 53 in the high-score group.